Developing Robust and Scale-able Peptide Isolation Processes
On Demand Webinar

Developing Robust and Scale-able Peptide Isolation Processes

On Demand Webinar

Identify, Understand and Mitigate Risks During Peptide Precipitation

Peptides are an important class of drug molecules due to their involvement in many physiological signaling pathways. However, isolation of peptides is difficult because most peptide isolation options generate amorphous material without the benefits of crystalline structure.

In this presentation, Emily Guinn and Kyle Blakely of Eli Lily discuss the development of a precipitation processes for several therapeutic peptides and the identification of critical risks, including:

  • Sticking to the reactor
  • Glassing upon isolation
  • Poor control of particle size
  • Difficulty controlling residual solvents

Development of processes to help mitigate these risks will be discussed including the use of Process Analytical Technology (PAT), in-process microscopy, Focused Beam Reflectance Measurement (FBRM) and Raman spectroscopy to better understand peptide precipitation processes and mitigate the risks posed by these difficulties.

Join the hundreds of researchers who already viewed this presentation.

Emily Guinn and Kyle Blakely – Eli Lilly
30 minutes
English

This page is not optimized for your web browser. Consider using a different browser or upgrade your browser to the latest version to ensure the best experience.